Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors

Familiar cancers represent a privileged point of view for studying the complex cellular events inducing tumor transformation. Von Hippel-Lindau syndrome, a familiar predisposition to develop cancer is a clear example. Here, we present our efforts to decipher the role of von Hippel-Lindau tumor suppressor protein (pVHL) in cancer insurgence. We collected high quality information about both pVHL mutations and interactors to investigate the association between patient phenotypes, mutated protein surface and impaired interactions. Our data suggest that different phenotypes correlate with localized perturbations of the pVHL structure, with specific cell functions associated to different protein surfaces. We propose five different pVHL interfaces to be selectively involved in modulating proteins regulating gene expression, protein homeostasis as well as to address extracellular matrix (ECM) and ciliogenesis associated functions. These data were used to drive molecular docking of pVHL with its interactors and guide Petri net simulations of the most promising alterations. We predict that disruption of pVHL association with certain interactors can trigger tumor transformation, inducing metabolism imbalance and ECM remodeling. Collectively taken, our findings provide novel insights into VHL-associated tumorigenesis. This highly integrated in silico approach may help elucidate novel treatment paradigms for VHL disease. Author summary Cancer is generally caused by a series of mutations accumulating over time in a healthy tissue, which becomes re-programmed to proliferate at the expense of the hosting organism. This process is difficult to follow and understand as events in a multitude of different genes can lead to similar outcomes without apparent cause. The von Hippel-Lindau (VHL) tumor suppressor is one of the few genes harboring a familiar cancer syndrome, i.e. VHL mutations are known to cause a predictable series of events leading cancer in the kidneys and a few selected other tissues. This article describes a large-scale analysis to relate known VHL mutations to specific cancer pathways by looking at the molecular interactions. Different cancer types appear to be caused by mutations changing the surface of specific parts of the VHL protein. By looking at the VHL interactors involved, it is therefore possible to identify other candidate genes for mutations leading to very similar cancer types.

[1]  R. Gatti,et al.  Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. , 2005, Haematologica.

[2]  S. Signoretti,et al.  VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 , 2008, Nature Cell Biology.

[3]  B. Raught,et al.  Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling* , 2016, The Journal of Biological Chemistry.

[4]  W. Kaelin,et al.  Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. , 2005, Cancer cell.

[5]  Claudio R. Thoma,et al.  Priming-Dependent Phosphorylation and Regulation of the Tumor Suppressor pVHL by Glycogen Synthase Kinase 3 , 2006, Molecular and Cellular Biology.

[6]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[7]  A. Kibel,et al.  Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.

[8]  Jun O. Liu,et al.  Nur77 Activated by Hypoxia-Inducible Factor-1α Overproduces Proopiomelanocortin in von Hippel-Lindau-Mutated Renal Cell Carcinoma , 2004, Cancer Research.

[9]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[10]  David W. Ritchie,et al.  Ultra-fast FFT protein docking on graphics processors , 2010, Bioinform..

[11]  H. Youn,et al.  The Positive Regulation of p53 by the Tumor Suppressor VHL , 2006, Cell cycle.

[12]  K. Huntoon,et al.  Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. , 2013, Cell reports.

[13]  Silvio C. E. Tosatto,et al.  MobiDB 3.0: more annotations for intrinsic disorder, conformational diversity and interactions in proteins , 2017, Nucleic Acids Res..

[14]  J. Cheng,et al.  pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner , 2016, Science.

[15]  J. Pouysségur,et al.  HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia , 2003, The EMBO journal.

[16]  T. Kietzmann,et al.  Glycogen Synthase Kinase 3 Phosphorylates Hypoxia-Inducible Factor 1α and Mediates Its Destabilization in a VHL-Independent Manner , 2007, Molecular and Cellular Biology.

[17]  J. Patard,et al.  Identification of pVHL as a Novel Substrate for Aurora-A in Clear Cell Renal Cell Carcinoma (ccRCC) , 2013, PloS one.

[18]  M. V. Panchenko,et al.  Jade-1, a candidate renal tumor suppressor that promotes apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  F. Sánchez‐Madrid,et al.  Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. , 2002, Cancer research.

[20]  Anushya Muruganujan,et al.  PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees , 2012, Nucleic Acids Res..

[21]  Vittorio Scarano,et al.  CONSRANK: a server for the analysis, comparison and ranking of docking models based on inter-residue contacts , 2015, Bioinform..

[22]  J. Klco,et al.  pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development , 2004, Molecular and Cellular Biology.

[23]  Silvio C. E. Tosatto,et al.  The RING 2.0 web server for high quality residue interaction networks , 2016, Nucleic Acids Res..

[24]  P. Ratcliffe,et al.  Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.

[25]  B. Ebert,et al.  pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. , 2007, Molecular cell.

[26]  W. Lim,et al.  Systematic Functional Prioritization of Protein Posttranslational Modifications , 2012, Cell.

[27]  J. Pelletier,et al.  The von Hippel-Lindau Protein pVHL Inhibits Ribosome Biogenesis and Protein Synthesis* , 2013, The Journal of Biological Chemistry.

[28]  Lars J. Jensen,et al.  Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells , 2016, Science Signaling.

[29]  A. V. D. van den Ouweland,et al.  Genetic analysis of von Hippel‐Lindau disease , 2010, Human mutation.

[30]  Sebastian A. Wagner,et al.  A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles* , 2011, Molecular & Cellular Proteomics.

[31]  M. Ohh,et al.  The multifaceted von Hippel–Lindau tumour suppressor protein , 2014, FEBS letters.

[32]  S. Weintraub,et al.  Proteomic dissection of the von Hippel-Lindau (VHL) interactome. , 2011, Journal of proteome research.

[33]  S. Tosatto,et al.  Isoform-specific interactions of the von Hippel-Lindau tumor suppressor protein , 2015, Scientific Reports.

[34]  S. Tosatto,et al.  Insights into the proline hydroxylase (PHD) family, molecular evolution and its impact on human health. , 2015, Biochimie.

[35]  E. Cho,et al.  p53 stabilization and transactivation by a von Hippel-Lindau protein. , 2006, Molecular cell.

[36]  M. Ohh,et al.  NEDD8 acts as a ‘molecular switch’ defining the functional selectivity of VHL , 2008, EMBO reports.

[37]  Y. Xiong,et al.  Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex. , 2015, Structure.

[38]  R. Conaway,et al.  von Hippel–Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Silvio C. E. Tosatto,et al.  VHLdb: A database of von Hippel-Lindau protein interactors and mutations , 2016, Scientific Reports.

[40]  Silvio C. E. Tosatto,et al.  Adding structural information to the von Hippel–Lindau (VHL) tumor suppressor interaction network , 2009, FEBS letters.

[41]  Gary D. Bader,et al.  An automated method for finding molecular complexes in large protein interaction networks , 2003, BMC Bioinformatics.

[42]  E. Voest,et al.  Tumor Suppression by the von Hippel-Lindau Protein Requires Phosphorylation of the Acidic Domain* , 2005, Journal of Biological Chemistry.

[43]  E. Robertson,et al.  Ubiquitin/SUMO Modification Regulates VHL Protein Stability and Nucleocytoplasmic Localization , 2010, PloS one.

[44]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Gygi,et al.  The Conserved Bardet-Biedl Syndrome Proteins Assemble a Coat that Traffics Membrane Proteins to Cilia , 2010, Cell.

[46]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[47]  Robert S. Freeman,et al.  Oxygen-Regulated β2-Adrenergic Receptor Hydroxylation by EGLN3 and Ubiquitylation by pVHL , 2009, Science Signaling.

[48]  William Y. Kim,et al.  Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia , 2011, Nature Medicine.

[49]  K. Hemminki,et al.  Familial cancers in a nationwide family cancer database: age distribution and prevalence. , 1999, European journal of cancer.

[50]  Yigong Shi Faculty Opinions recommendation of Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. , 2002 .

[51]  G. Semenza,et al.  FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .

[52]  Andrew N Freedman,et al.  Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey , 2010, Genetics in Medicine.

[53]  J. Vandekerckhove,et al.  Prefoldin, a Chaperone that Delivers Unfolded Proteins to Cytosolic Chaperonin , 1998, Cell.

[54]  D. Pignatelli,et al.  Von Hippel–Lindau disease: a single gene, several hereditary tumors , 2017, Journal of Endocrinological Investigation.

[55]  E. Cho,et al.  Nur77 upregulates HIF-alpha by inhibiting pVHL-mediated degradation. , 2008, Experimental & molecular medicine.

[56]  W. Krek,et al.  pVHL: A Multipurpose Adaptor Protein , 2008, Science Signaling.

[57]  D. Orth,et al.  Proopiomelanocortin gene expression in a pheochromocytoma using upstream transcription initiation sites. , 1988, Biochemical and biophysical research communications.

[58]  W. Krek,et al.  The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. , 2004, Trends in molecular medicine.

[59]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[60]  E. Robertson,et al.  Hypoxia Inactivates the VHL Tumor Suppressor through PIASy-Mediated SUMO Modification , 2010, PloS one.

[61]  D. Seldin,et al.  Jade-1 inhibits Wnt signaling by ubiquitinating β-catenin and mediates Wnt pathway inhibition by pVHL , 2008, Nature Cell Biology.

[62]  J. Bruder,et al.  VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. , 1999, Biochemical and biophysical research communications.

[63]  Emmanuel Ampofo,et al.  Phosphorylation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1alpha mediated transcription. , 2010, The international journal of biochemistry & cell biology.

[64]  S. Gygi,et al.  Regulation of Cellular Levels of Sprouty2 Protein by Prolyl Hydroxylase Domain and von Hippel-Lindau Proteins* , 2011, The Journal of Biological Chemistry.

[65]  M. Ohh,et al.  The HIF and other quandaries in VHL disease , 2018, Oncogene.

[66]  E. Messing,et al.  Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel—Lindau protein , 2003, The EMBO journal.

[67]  Andrea Gazzo,et al.  PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update , 2017, Nucleic Acids Res..

[68]  P. Heikkilä,et al.  HuR in pheochromocytomas and paragangliomas – overexpression in verified malignant tumors , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[69]  C. Heinlein,et al.  The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. , 2002, Molecular endocrinology.

[70]  E. Maher,et al.  VHL, the story of a tumour suppressor gene , 2014, Nature Reviews Cancer.

[71]  R. Burk,et al.  Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation. , 2008, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[72]  E. Cho,et al.  Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation , 2011, Cell cycle.

[73]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[74]  Olga G. Troyanskaya,et al.  GIANT 2.0: genome-scale integrated analysis of gene networks in tissues , 2018, Nucleic Acids Res..

[75]  Wei Zhang,et al.  The von hippel-lindau protein suppresses androgen receptor activity. , 2014, Molecular endocrinology.

[76]  William Y. Kim,et al.  Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL , 2011, Journal of cellular and molecular medicine.

[77]  P. Ratcliffe,et al.  Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor* , 2007, Journal of Biological Chemistry.

[78]  A. Zharkikh,et al.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral , 2005, Journal of Medical Genetics.

[79]  Fernand Labrie,et al.  Comparison of crystal structures of human androgen receptor ligand‐binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity , 2006, Protein science : a publication of the Protein Society.

[80]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[81]  A. Pause,et al.  Collagen matrix assembly is driven by the interaction of von Hippel–Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2 , 2008, Oncogene.

[82]  David S. Goodsell,et al.  The RCSB protein data bank: integrative view of protein, gene and 3D structural information , 2016, Nucleic Acids Res..

[83]  D. Mukhopadhyay,et al.  Role of elongin-binding domain of von hippel lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma , 2005, Oncogene.

[84]  V. Venkataramanan,et al.  The deubiquitinases USP33 and USP20 coordinate β2 adrenergic receptor recycling and resensitization , 2009, The EMBO journal.

[85]  Manfred Auer,et al.  The x-ray crystal structure of the first RNA recognition motif and site-directed mutagenesis suggest a possible HuR redox sensing mechanism. , 2010, Journal of molecular biology.

[86]  E. Cho,et al.  Nur77 upregulates HIF-α by inhibiting pVHL-mediated degradation , 2008, Experimental & Molecular Medicine.

[87]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[88]  K. Dyer,et al.  Hsp70RY: further characterization of a novel member of the hsp70 protein family. , 1994, Biochemical and biophysical research communications.

[89]  A. Tabarin,et al.  One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.

[90]  S. Tosatto,et al.  Design and Analysis of a Petri Net Model of the Von Hippel-Lindau (VHL) Tumor Suppressor Interaction Network , 2014, PloS one.

[91]  C. Stiller Epidemiology and genetics of childhood cancer , 2004, Oncogene.

[92]  Silvio C. E. Tosatto,et al.  FELLS: fast estimator of latent local structure , 2017, Bioinform..

[93]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[94]  Peter L. Choyke,et al.  Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease , 2016, Nature Reviews Clinical Oncology.

[95]  Svetlana V. Harbaugh,et al.  The von Hippel-Lindau Tumor Suppressor Protein and Egl-9-Type Proline Hydroxylases Regulate the Large Subunit of RNA Polymerase II in Response to Oxidative Stress , 2008, Molecular and Cellular Biology.

[96]  G. Mills,et al.  Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function , 2016, Oncogene.